ADMA Biologics (NASDAQ: ADMA) reported Q1 EPS of $0.19, $0.01 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $114.5 million versus the consensus estimate of $142.74 million.

GUIDANCE:

ADMA Biologics sees FY2026 revenue of $530-560 million, versus the consensus of $630 million.

• FY 2026 total revenue expected to be $530 million to $560 million
• FY 2026 Adjusted Net Income expected to be $170 million to $200 million
• FY 2026 Adjusted EBITDA expected to be $265 million to $300 million
• Withdrawing previously provided long-term guidance due to current competitive dynamics in the PDT & IG market

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.